PHP
DXCM icon

Parkman Healthcare Partners’s DexCom DXCM Stock Holding History

Parkman Healthcare Partners’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36M Sell
534,767
-155,055
-22% -$10.3M 3.69% 4
2026
Q1 		$43.3M Buy
689,822
+102,347
+17% +$7.13M 4.47% 2
2025
Q4 		$39M Buy
587,475
+415,847
+242% +$26.9M 3.71% 3
2025
Q3 		$11.5M Sell
171,628
-54,247
-24% -$4.29M 1.2% 31
2025
Q2 		$19.7M Buy
225,875
+95,508
+73% +$7.49M 2.27% 13
2025
Q1 		$8.9M Buy
130,367
+51,817
+66% +$4.23M 1.06% 36
2024
Q4 		$6.11M Buy
78,550
+7,962
+11% +$589K 0.81% 41
2024
Q3 		$4.73M Sell
70,588
-86,267
-55% -$7.08M 0.6% 54
2024
Q2 		$17.8M Sell
156,855
-14,810
-9% -$1.87M 2.38% 10
2024
Q1 		$23.8M Sell
171,665
-53,950
-24% -$6.78M 2.92% 7
2023
Q4 		$28M Sell
225,615
-39,903
-15% -$4.08M 3.94% 4
2023
Q3 		$24.8M Buy
265,518
+180,392
+212% +$20.3M 4.54% 4
2023
Q2 		$10.9M Buy
85,126
+6,199
+8% +$750K 1.9% 16
2023
Q1 		$9.17M Buy
78,927
+16,197
+26% +$1.81M 1.99% 17
2022
Q4 		$7.1M Buy
62,730
+22,372
+55% +$2.46M 1.89% 14
2022
Q3 		$3.25M Buy
40,358
+5,524
+16% +$468K 0.92% 40
2022
Q2 		$2.6M Sell
34,834
-16,114
-32% -$1.47M 0.96% 37
2022
Q1 		$6.52M Sell
50,948
-80,676
-61% -$8.82M 1.91% 19
2021
Q4 		$17.7M Sell
131,624
-50,208
-28% -$7.21M 3.9% 5
2021
Q3 		$24.9M Sell
181,832
-20,000
-10% -$2.52M 6.29% 1
2021
Q2 		$21.5M Buy
201,832
+50,960
+34% +$4.89M 4.71% 2
2021
Q1 		$13.6M Sell
150,872
-15,240
-9% -$1.43M 3.15% 8
2020
Q4 		$15.4M Buy
166,112
+47,836
+40% +$4.27M 3.93% 1
2020
Q3 		$12.2M Sell
118,276
-11,964
-9% -$1.25M 3.23% 5
2020
Q2 		$13.2M Buy
130,240
+2,108
+2% +$189K 3.72% 4
2020
Q1 		$8.63M Sell
128,132
-11,868
-8% -$739K 4% 6
2019
Q4 		$7.66M Buy
+140,000
New +$6.64M 2.21% 17

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Parkman Healthcare Partners's DXCM Position: Q2 2026 in Review

Parkman Healthcare Partners reduced its DexCom (DXCM) stake by 22% in Q2 2026, selling an estimated $10.3M and leaving 534,767 shares worth $36M. The position accounts for 3.69% of the portfolio, ranked #4.

Parkman Healthcare Partners first reported a position in DXCM in Q4 2019 and has held it in 27 quarters since. The position peaked at $43.3M in Q1 2026. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Parkman Healthcare Partners held 534,767 shares of DexCom worth $36M as of Q2 2026.
  • Parkman Healthcare Partners sold 155,055 DexCom shares in Q2 2026, an estimated $10.3M.
  • DexCom made up 3.69% of Parkman Healthcare Partners's portfolio in Q2 2026, its #4 holding.
  • Parkman Healthcare Partners first reported a position in DexCom in Q4 2019 and has held it in 27 quarters since.
  • Parkman Healthcare Partners's DexCom position peaked at $43.3M in Q1 2026.
  • 973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.